Plioplys A V
Mercy Hospital and Medical Center, and the Department of Neurology, University of Illinois, Chicago 60616, USA.
J Child Neurol. 1998 Feb;13(2):79-82. doi: 10.1177/088307389801300207.
Since autism has been associated with immunologic abnormalities suggesting an autoimmune cause of autistic symptoms in a subset of patients, this study was undertaken to investigate whether intravenous immunoglobulin (i.v.Ig) would improve autistic symptoms. Ten autistic children with immunologic abnormalities, demonstrated on blood tests, were enrolled in this study. Their ages ranged from 4 to 17 years, with two girls and eight boys. Eight children (1 female and 7 male) historically had undergone autistic regression. Intravenous immunoglobulin, 200 to 400 mg/kg, was administered every 6 weeks for an intended treatment program of four infusions. In five children, there was no detectable change in behavior during the treatment program. In four children, there was a mild improvement noted in attention span and hyperactivity. In none of these children did the parents feel that the improvement was sufficient to warrant further continuation of the infusions beyond the termination of the program. Only in one child was there a very significant improvement, with almost total amelioration of autistic symptoms over the time period of the four infusions. Once the treatment program was completed, this child gradually deteriorated over a 5-month time period and fully reverted to his previous autistic state. In this treatment program, five children had no response to intravenous immunoglobulin. In the four children who showed mild improvements, those improvements may simply have been due to nonspecific effects of physician intervention and parental expectation (ie, placebo effect). However, in one child there was a very significant amelioration of autistic symptoms. There were no distinguishing historic or laboratory features in this child who improved. Given a positive response rate of only 10% in this study, along with the high economic costs of the immunologic evaluations and the intravenous immunoglobulin treatments, the use of intravenous immunoglobulin to treat autistic children should be undertaken only with great caution, and only under formal research protocols.
由于自闭症与免疫异常有关,这表明在一部分患者中自闭症症状存在自身免疫性病因,因此开展了本研究以调查静脉注射免疫球蛋白(i.v.Ig)是否会改善自闭症症状。本研究纳入了10名血液检查显示有免疫异常的自闭症儿童。他们的年龄在4至17岁之间,其中有2名女孩和8名男孩。8名儿童(1名女性和7名男性)既往有自闭症退化史。每6周静脉注射200至400mg/kg免疫球蛋白,计划进行4次输注的治疗方案。在5名儿童中,治疗期间行为无明显变化。在4名儿童中,注意广度和多动有轻度改善。这些儿童的家长均认为这种改善程度不足以保证在治疗方案结束后继续进行输注。只有1名儿童有非常显著的改善,在4次输注期间自闭症症状几乎完全缓解。治疗方案完成后,该儿童在5个月内逐渐恶化,完全恢复到之前的自闭症状态。在这个治疗方案中,5名儿童对静脉注射免疫球蛋白无反应。在4名有轻度改善的儿童中,这些改善可能仅仅是由于医生干预和家长期望的非特异性效应(即安慰剂效应)。然而,有1名儿童自闭症症状有非常显著的改善。在这名改善的儿童中,没有可区分的病史或实验室特征。鉴于本研究中阳性反应率仅为10%,以及免疫评估和静脉注射免疫球蛋白治疗的高经济成本,使用静脉注射免疫球蛋白治疗自闭症儿童应极其谨慎,且仅在正式研究方案下进行。